Form 4: Pasithea Therapeutics Corp. Insider Stock Option Grant

Kartik Krishnan, Chief Medical Officer of Pasithea Therapeutics Corp., received a stock option grant for 1,129,323 shares.

Summary

• Kartik Krishnan, Chief Medical Officer of Pasithea Therapeutics Corp. (KTTA), was granted a stock option on May 1, 2026.
• The option allows for the purchase of 1,129,323 shares of common stock at an exercise price of $0.84 per share.
• The shares underlying the option will vest over a period of approximately two years, with 33% vesting one year after the grant date and the remainder vesting quarterly thereafter.
• Full vesting is triggered upon a Change in Control of the company.
• The option remains exercisable for three years following termination of service, unless terminated for Cause.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard stock option grant to an executive, which is typical for the industry and does not inherently signal positive or negative company performance on its own.

Positives

• Grant of stock options to a key executive (Chief Medical Officer) indicates a commitment to retaining and incentivizing leadership.
• The vesting schedule is tied to continued service and company performance (Change in Control), aligning executive interests with shareholder value.
• The exercise price of $0.84 suggests the option was granted at or near the market price at the time, potentially offering upside potential.

Negatives

• The filing does not provide information on the company's current financial performance or operational status, making it difficult to assess the intrinsic value of the option grant.
• The vesting schedule, while standard, means the full benefit of the option is not immediately realized by the executive.

Risks

• The value of the stock options is directly tied to the future performance and stock price of Pasithea Therapeutics Corp., which carries inherent market and business risks.
• If the reporting person's service is terminated for Cause, the option may not be exercisable.
• The option is subject to the terms and conditions of the Issuer's 2023 Stock Incentive Plan, which could have further implications.

Future Outlook

The future outlook for the stock options is dependent on the company's performance and stock price appreciation, as well as the reporting person's continued service. The options are exercisable for a period of up to three years post-termination, providing some flexibility.

Management Comments

• The option award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended.
• The shares underlying the Option will vest at the rate of 33% upon the one-year anniversary of the date of grant and the remaining shares will vest in equal quarterly installments thereafter for the next two years.
• Vesting is contingent upon the Reporting Person remaining in continuous service to the Issuer through such vesting dates.
• The shares underlying the Option will fully vest upon a Change in Control.
• All vested and exercisable shares underlying the Option held by the grantee may be exercised by the grantee for a period of up until three (3) years following termination of Continuous Service, other than a termination for Cause.

Industry Context

StockSavvy.ai notes that the grant of stock options to a Chief Medical Officer is a common practice in the biotechnology and pharmaceutical sectors to attract, retain, and incentivize key scientific and medical leadership, aligning their interests with long-term company growth and value creation.

Stakeholder Impact

• Shareholders: The grant of options dilutes existing shareholders' equity, but it also serves as an incentive for executive performance, which could lead to increased shareholder value if successful.
• Employees: This grant is specific to the Chief Medical Officer and does not directly impact other employees, though it reflects the company's compensation strategy.
• Management: The Chief Medical Officer is incentivized to perform well and remain with the company to realize the full value of the options.

Next Steps

• The reporting person will continue to serve the company, working towards the vesting of the stock options.
• The company's performance will determine the ultimate value of the vested options.
• The option holder may exercise vested options according to the plan's terms.

Key Dates

Keywords

stock option, insider trading, Pasithea Therapeutics Corp., KTTA, Kartik Krishnan, Chief Medical Officer, equity award, vesting schedule, SEC Form 4